Increased HIV-1 Immunogenicity of Replication Competent NYVAC

Background: The human RV144 efficacy trial revealed a 31% efficacy rate against acquisition of HIV infection using the ALVACvcp1521/ AIDSVAX gp120 B/E prime boost regimen. In addition to a modest efficacy rate, the duration of protection was relatively short-lived, suggesting that both vaccine compo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:AIDS research and human retroviruses 2013-11, Vol.29 (11), p.A-160
Hauptverfasser: Heeney, J L, Jacobs, B, Esteban, M, Wagner, R, Foulds, K, Roederer, M, Self, S, Barnett, S, Tartaglia, J, Montefiori, D, Tomaras, G, Pantaleo, G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: The human RV144 efficacy trial revealed a 31% efficacy rate against acquisition of HIV infection using the ALVACvcp1521/ AIDSVAX gp120 B/E prime boost regimen. In addition to a modest efficacy rate, the duration of protection was relatively short-lived, suggesting that both vaccine components must be improved. The Copenhagen vaccinia derived replication deficient NYVAC has been shown to be highly immunogenic in combination with DNA priming in both non-human primates (NHPs) and human clinical trials.
ISSN:0889-2229